Cellectar, SpectronRx sign agreement to manufacture iopofosine I 131

SpectronRx and Cellectar Biosciences (CLRB) have signed a commercial supply agreement for the manufacture of Cellectar’s first-in-class cancer therapy, iopofosine I 131. “We continue strengthening our supply network, ensuring patients with advanced cancers in need of novel therapeutic options gain access to what we believe is a best-in-class treatment for Waldenstrom’s macroglobulinemia. This partnership is part of our multi-sourced global supply strategy, which is key for Cellectar’s commercialization plans for iopofosine I 131,” said James Caruso, president and CEO of Cellectar. “SpectronRx’s expertise and strategically located facilities offer significant logistical benefits for global market distribution while expanding our manufacturing capabilities for iopofosine I 131.”